A study compared the association of semaglutide vs other antidiabetic medications and other GLP-1RAs, including liraglutide and dulaglutide, with opioid overdose risk in patients with comorbid type 2 diabetes (T2D) and opioid use disorder (OUD).
Novo Nordisk A/S’ (NYSE:NVO) semaglutide is available as Wegovy and Ozempic for weight loss and diabetes, respectively, and liraglutide is sold as Saxenda and Victoza.
Also Read: EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet ‘The Real Issue Is With The Middlemen’.
Eli Lilly And Co’s (NYSE:LLY) dulaglutide is available as Trulicity.
Drug overdose deaths in the U.S. remain alarmingly high, with an estimated 107,543 fatalities in 2023, primarily due to opioids.
Despite ...
